Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Assess the Efficacy of the Anti-PD-L1 Antibody Atezolizumab (MPDL3280A) Administered With Stereotactic Ablative Radiotherapy (SABR) in Patients With Metastatic Tumours

Next Previous
X
Search
Trial Profile

A Phase II Study to Assess the Efficacy of the Anti-PD-L1 Antibody Atezolizumab (MPDL3280A) Administered With Stereotactic Ablative Radiotherapy (SABR) in Patients With Metastatic Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Soft tissue sarcoma; Tumours
  • Focus Therapeutic Use
  • Acronyms SABR-PDL1

    • Most Recent Events

    • 14 May 2024 Planned End Date changed from 1 Oct 2020 to 1 Oct 2024.
    • 14 May 2024 Status changed from recruiting to active, no longer recruiting.
    • 24 Oct 2023 Results (n=60) assessing colorectal (CRC) cohort of the SABR-PDL1 trial that evaluated the PD-L1 inhibitor atezolizumab in combination with stereotactic body radiation therapy (SBRT) in advanced cancer patients, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top